ArticleRegenerative therapy2026
Bypassing pluripotency: The promise of direct differentiation from reaggregated micro-fat into multilineage organoids.
Article in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organoid technologies have emerged as powerful tools in regenerative medicine; however, current organoid technologies are predominantly based on pluripotent stem cell-derived systems, which poses challenges related to complexity, maturation, and clinical translation. In this commentary, we highlight a recent study by Huang et al. describing a tissue-level strategy for direct generation of functional multilineage organoids from human adult adipose tissue using reaggregated micro-fat (RMF). By preserving native tissue architecture and cellular heterogeneity, this approach enables the formation of mesoderm-, endoderm-, and ectoderm-derived organoids without genetic reprogramming or prolonged expansion culture. RMF-derived organoids demonstrate functional properties in vivo, including support of hematopoiesis and restoration of glycemic control in disease models. While further optimization and standardization will be required for clinical translation, this work provides a compelling alternative to conventional pluripotent stem cell-based paradigms and underscores the importance of tissue context in regenerative strategies. The study reframes adipose tissue as an integrated regenerative substrate and broadens the conceptual landscape of organoid generation toward more clinically accessible approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.